Novartis Scores Back-To-Back Jury Wins in Bone Cancer Drug Labeling Suits


Novartis and Hollingsworth, its national counsel in litigation over the cancer drug Zometa, got a double dose of good news in the past week with federal juries in Kentucky and St. Louis throwing out failure-to-warn claims by plaintiffs who blamed the company for their jaw disease.

This premium content is reserved for American Lawyer subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202541365010

Thank you!

This article's comments will be reviewed.